{"title": "PDF", "author": "PDF", "url": "https://health.mo.gov/living/wellness/immunizations/pdf/shingles92117.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Kenneth Schmader, MD Professor of Medicine -Geriatrics Duke University and Durham VA Medical Centers Zoster Vaccines in Older Adults September 21, 2017 The Clinical Problem . . . 78 year old man in good health working as the CEO of a company . . . 2 . . neuralgia for . . . from the start of the shingles until now, I don't know, it's been 50 some days. The pain has worn me down to the last straw. I am at the end of my line. I got to have somebody do something. I desperately, desperately need help. I don't know how much longer I can take it. 3 Pain is the Cardinal Problem Posed by Herpes Zoster in Older Adults -- Acute and Chronic Pain Schmader KE, Dworkin RH. Herpes Zoster and Postherpetic Neuralgia. Essentials of Pain Medicine 4th ed 4 Acute and Postherpetic Neuralgia Adverse Impact on Multiple Domains of Health Physical Psychological Fatigue Anorexia Weight loss Physical inactivity Insomnia Depression Anxiety Difficulty concentrating Social Functional Decreased social gatherings Change in social role Interfere with basic and instrumental activities of daily living -Dressing, Bathing, Eating, Mobility -Travelling, Cooking, Housework, Shopping Schmader KE. of Varicella Zoster Virus 7 Age and of Herpes Zoster Kawai et al. BMJ Open 2014;4:e004833 8 9 Strategies to Enhance Protection of Older Adults Against Vaccine -Preventable Diseases Improve Immune Response to cell-free preparation of Oka/Merck strain VZV Contains whole live viral antigen and Neomycin, sucrose, gelatin, glutamate, inorganic salts Formulated to contain substantially more live virus and viral antigen than are contained in the varicella vaccine www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm 11 Shingles Prevention Study Design: Randomized, double -blind, placebo - controlled, stratified by age, 60 -69 and 70 years Setting: 22 US sites (16 VA and 6 university medical centers) Participants: 38,546 immunocompetent adults 60 years old -19,270 zoster vaccine -19,276 placebo Oxman M et al. N Engl J Med. 2005;352:2271 -2284 12 Shingles Prevention Study Intervention: One dose of live attenuated zoster vaccine or placebo Outcomes: Incidence of HZ and PHN and Pain Burden of Illness (BOI) Oxman M et al. N Engl J Med. 2005;352:2271 -2284 13 Incidence of herpes zoster (per 1000 person years) 5.4 3.9 10.7 11.1 0 2 4 6 8 10 12 14 All Subjects Age 60 -69 70 Placebo Zoster Vaccine Live 51.3% (44.2 -57.6) 7.2 11.5 Oxman (per 1000 person years) 0.46 0.26 0.74 1.38 0 0.5 1.0 1.5 2.0 2.5 All Subjects Age 60 -69 70 Placebo Zoster Vaccine Live 66.5% Live Schmader KE et al. Clin Infect Dis 2012;54:922 -8 Incidence of herpes zoster (per 1000 person years) 1.99 6.60 0 2 4 6 8 10 (54.1 -80.6) Efficacy (95% CI) 11,228 Zoster Vaccine on Incidence of Herpes Zoster in Persons 50 -59 Years Old 17 How Persistent is the Effect of the Live Zoster Vaccine? VA CSP #403B: The Short - Term Persistence Substudy * Follow -up 3.3 to 7.8 years Comparator: Placebo Vaccine Efficacy for HZ: 39.6% VA CSP #403C: The Long - Term Persistence Substudy ** Follow -up 4.7 to 11.6 years Comparator: Historical controls Vaccine Efficacy for HZ: 21% *Schmader KE et al. Clin Infect Dis 2012;55(10):1320 **Morrison V et al. Clin Infect Dis 2015;60:900 -909 18 Efficacy of Live Zoster Vaccine on Herpes Zoster by Year After Vaccination SPS = Shingles Prevention Study: STPS = Short -Term Persistence Substudy ; LTPS = Long -Term Persistence Substudy Morrison et al. Clin Infect Dis. 2015;60:900 -909; Schmader KE et al. Clin Infect Dis 2012;55:1320 -8 19 So . . .What about a booster dose? Live zoster vaccine administered as a booster dose 10 years after first dose in individuals 70 years old -Significantly increases immunity to VZV -Increase in VZV immunity in the booster dose group is significantly higher than matched first -time immunization group for one year after immunization But clinical significance of immunological findings is unknown . . . -ACIP does not recommend a second dose of live zoster vaccine at this time Levin MJ, Schmader KE, et al. J Infect Dis 2016;213:14 -22 20 Strategies to Enhance Protection of Older Adults Against Vaccine -Preventable Diseases Improve Immune Response to An adjuvant is a substance that potentiates the immune response to an antigen Reed et al. Nature Medicine 2013;19:1597 -1608 Adjuvanted Zoster Subunit -based AS01b adjuvant Lipsome is a spherical vesicle having least one lipid bilayer AS01b Design: Randomized, double -blind, placebo - controlled in persons 50 years old, stratified by age, 50 -59, 60 -69, 70 -79, 80 Setting: Multiple centers in North America, Europe, Latin America, Asia -Pacific Participants: 14,759 immunocompetent adults -7344 zoster vaccine Med 2015;372:2087 -2096 24 Adjuvanted Zoster Subunit ZOE -50 Intervention: 2 doses of subunit zoster vaccine or placebo at 2 month intervals Outcomes: Incidence of HZ and PHN Lal et al. New Engl J Med 2015;372:2087 -2096 25 Efficacy of Adjuvanted Zoster Subunit Vaccine ZOE -50 Vaccine (n=7344) Placebo (n=7415) Vaccine Efficacy % (95% CI) HZ Cases (n) Incidence per 1000 person -yrs HZ Cases (n) Incidence per 1000 person -yrs 6 0.3 210 9.1 97.2 (93.7 - 99.0) Lal et al. New Engl J 2015;372:2087 -2096 26 ZOE-50 Adverse Events and Reactogenicity Reactogenicity Subgroup Within 7 Days After Vaccination Variable Vaccine % (95% CI)* Placebo % (95% CI)* Any adverse event 84.4 (83.3 -85.5) 37.8 (36.4 -39.3) -Grade 3 vaccination related 15.6 (14.5 -16.7) 1.9 (1.5-2.3) Injection site reaction 81.5 (80.3 -82.6) 11.9 (11.0 -12.9) reaction 3 (10.5 -12.4) Lal et al. New Engl J Med 2015;372:2087 -2096 Vaccine n = 4460, Placebo n = 4466 Grade 3 - prevented normal activity 27 ZOE-50 Adverse Events and Reactogenicity Total Cohort Throughout Study Period Variable Vaccine % (95% CI)* Placebo % (95% CI)* Serious adverse event 9.0 (8.3 -9.6) 8.9 (8.3 -9.6) Potential immune - mediated disease 1.0 (0.8 -1.3) 1.3 (1.0 -1.5) Death 2.2 (1.9 -2.5) 2.3 (1.9-2.6) Lal et al. New Engl J Med 2015;372:2087 -2096 *Vaccine n = 7698, Adjuvanted Zoster Subunit Vaccine ZOE-70 Placebo (n=6622) Vaccine Efficacy % (95% CI) HZ Cases (n) Incidence per 1000 person -yrs HZ Cases (n) Incidence per 1000 person -yrs 23 0.9 223 9.2 89.8 (84.2 -93.7) Cunningham AL, et al. N Engl J Med 2016;375:0191 -1032 29 US Vaccination Coverage among Older Adults for Zoster Vaccine, 2015 Vaccine Coverage (%) Zoster, ever 31 National Health Interview Survey, United States, 2015 https ://www.cdc.gov/vaccines/imz -managers/coverage/adultvaxview/coverage - estimates/2015.html#table5 30 "}